CliffBio
small molecule

CETROTIDE

CETRORELIX ACETATE

Loss of exclusivity—loss of exclusivity
CompanyEMD Serono →See this company's full patent-cliff portfolio

Drug detail

Brand nameCETROTIDE
Active ingredientCETRORELIX ACETATE
StrengthEQ 0.25MG BASE/VIAL
Dosage formPOWDER
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalAugust 2000
Marketing statusRX

More from EMD Serono

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CETROTIDE patent cliff — loss of exclusivity — | CliffBio